Insulin therapy: Associated challenges in Type 2 Diabetes

The study was to assess challenges associated with insulin therapy in people with type 2 diabetes and how these challenges can be resolved to increase patient safety and quality of life. Participants of both sexes between the ages of 20 and 59 years were enrolled across successive samples and assessed for the prevalence of type 2 diabetes, hypertension (whether hypertensive or not), dyslipidemia, and smoking status. Weight gain and hypoglycemia are the primary diagnostic and outcome criteria for type 2 diabetes when taking insulin therapy. According to the study, only 27.27% of type 2 diabetes patients were receiving oral antidiabetic drug monotherapy, while 72.72% were receiving antidiabetic drug combination therapy. Only 43.75% of the 72.72% of patients who received antidiabetic prescription combination medication received triple combination therapy, whereas 56.25% received dual combination therapy. It was concluded that participants undergoing conventional therapy are at a higher risk of hypoglycemia but a much lower risk of weight gain and other complications. Due to a lack of cultural understanding regarding these risk factors for weight gain and their modifiable risk factors, both individual and public health measures could be warranted.